Slate Medicines is a biotechnology company focused on developing next generation therapeutics targeting PACAP for the treatment and prevention of migraine and other headache disorders.
Location: United States
Total raised: $130M
Investors 1
| Date | Name | Website |
| 24.08.2026 | Foresite C... | foresiteca... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.02.2026 | Series A | $130M | Foresite C... |
Mentions in press and media 6
| Date | Title | Description |
| 26.02.2026 | Slate Medicines Secures $130M to Advance Migraine Prevention | Slate Medicines secures $130 million in Series A funding. The Raleigh, NC-based biotech company launched to transform migraine prevention. Its core focus is SLTE-1009, an anti-PACAP monoclonal antibody. This therapy addresses severe headach... |
| 24.02.2026 | Slate Medicines: $130 Million Series A Raised To Advance Anti-PACAP Migraine Therapies | Slate Medicines, a privately held biotech company developing next-generation therapeutics for headache disorders, has launched with the close of a $130 million Series A financing and the in-licensing of SLTE-1009, an anti-PACAP monoclonal a... |
| 24.02.2026 | Slate Medicines Raises $130M in Series A Funding | Slate Medicines, a Raleigh, NC-based biotech company, raised $130M in Series A funding. The round was led by RA Capital Management, Forbion, and Foresite Capital with participation from an additional undisclosed biotech investor. In conjunc... |
| 24.02.2026 | Slate Medicines Launches With $130M Series A | RALEIGH, NC, Slate Medicines, a privately-held biotech company advancing next-generation therapeutics for headache disorders, today announced the close of a $130 million Series A round. >> Click here for more funding data on Slate Me... |
| - | Slate Medicines | “Slate Medicines is a biotechnology company focused on developing next generation therapeutics targeting PACAP for the treatment and prevention of migraine and other headache disorders.” |
| - | Slate Medicines | - |